Drug Action
Supplements of pancreatin are given to compensate for reduced or absent exocrine secretion. They assist the digestion of starch, fat, and protein.
PDF page 125
Loading InternPractice…
Drug reference
Supplements of pancreatin are given to compensate for reduced or absent exocrine secretion. They assist the digestion of starch, fat, and protein.
PDF page 125
CREON ® 10000 Pancreatic insufficiency ▶BY MOUTH ▶Child: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing) ▶Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing) CREON ® 25000 Pancreatic insufficiency ▶BY MOUTH ▶Child 2–17 years: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed continued → immediately without chewing) ▶Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately Gastro-intestinal system without chewing) CREON ® 40000 Pancreatic insufficiency ▶BY MOUTH ▶Child 2–17 years: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing) ▶Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing) CREON ® MICRO Pancreatic insufficiency ▶BY MOUTH ▶Child: Initially 100 mg, for administration advice, see Directions for administration ▶Adult: Initially 100 mg, for administration advice, see Directions for administration DOSE EQUIVALENCE AND CONVERSION ▶For Creon ® Micro : 100 mg granules = one measured scoopful (scoop supplied with product). NUTRIZYM 22 ® GASTRO-RESISTANT CAPSULES Pancreatic insufficiency ▶BY MOUTH ▶Adult: Initially 1–2 capsules, dose to be taken with meals and 1 capsule as required, dose to be taken with snacks, doses should be swallowed whole or contents taken with water, or mixed with acidic fluid or soft food (then swallowed immediately without chewing) PANCREASE HL ® Pancreatic insufficiency ▶BY MOUTH ▶Child 15–17 years: Initially 1–2 capsules, dose to be taken during each meal and 1 capsule, to be taken with snacks, all doses either taken whole or contents mixed with slightly acidic liquid or soft food (then swallowed immediately without chewing) ▶Adult: Initially 1–2 capsules, dose to be taken during each meal and 1 capsule, to be taken with snacks, all doses either taken whole or contents mixed with slightly acidic liquid or soft food (then swallowed immediately without chewing) PANCREX ® V Pancreatic insufficiency ▶BY MOUTH ▶Child 1–11 months: 1–2 capsules, contents of capsule to be mixed with feeds ▶Child 1–17 years: 2–6 capsules, dose to be taken with each meal either swallowed whole or sprinkled on food ▶Adult: 2–6 capsules, dose to be taken with each meal either swallowed whole or sprinkled on food PANCREX ® V POWDER Pancreatic insufficiency ▶BY MOUTH ▶Child: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water ▶Adult: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water
PDF pages 125, 126
Can irritate the perioral skin and buccal mucosa if retained in the mouth. excessive doses can cause perianal irritation
PDF page 126
Preparations may contain pork pancreatin—consult product literature. l HANDLING AND STORAGE Hypersensitivity reactions have occasionally occurred in those handling the powder.
PDF page 126
→Appendix 1: pancreatin
PDF page 126
▶Common or very common Abdominal distension. constipation. nausea. vomiting ▶Uncommon Skin reactions ▶Frequency not known Fibrosing colonopathy
PDF page 126
Not known to be harmful.
PDF page 126
Pancreatin is inactivated by gastric acid therefore manufacturer advises pancreatin preparations are best taken with food (or immediately before or after food). Since pancreatin is inactivated by heat, excessive heat should be avoided if preparations are mixed with liquids or food; manufacturer advises the resulting mixtures should not be kept for more than one hour and any left-over food or liquid containing pancreatin should be discarded. Enteric-coated preparations deliver a higher enzyme concentration in the duodenum (provided the capsule contents are swallowed whole without chewing). Manufacturer advises gastro- resistant granules should be mixed with slightly acidic soft food or liquid such as apple juice, and then swallowed immediately without chewing. Capsules containing enteric-coated granules can be opened and the granules administered in the same way. For infants, Creon ® Micro granules can be mixed with a small amount of milk on a spoon and administered immediately—granules should not be added to the baby’s bottle. Manufacturer advises Pancrex ® V powder may be administered via nasogastric tube or gastrostomy tube—consult local and national official guidelines.
PDF page 126
There can be variation in the licensing of different medicines containing the same drug. Gastro-resistant capsule ▶Creon (Mylan) Protease 600 unit, Amylase 8000 unit, Lipase 10000 unit Creon 10000 gastro-resistant capsules | 100 capsule p £12.93 Protease 1000 unit, Amylase 18000 unit, Lipase 25000 unit Creon 25000 gastro-resistant capsules | 100 capsule P £28.25 ▶Nutrizym (Merck Serono Ltd) Protease 1100 unit, Amylase 19800 unit, Lipase 22000 unit Nutrizym 22 gastro-resistant capsules | 100 capsule P £33.33 ▶Pancrease (Janssen-Cilag Ltd) Protease 1250 unit, Amylase 22500 unit, Lipase 25000 unit Pancrease HL gastro-resistant capsules | 100 capsule P £40.38 Gastro-resistant granules CAUTIONARY AND ADVISORY LABELS 25 ▶Creon (Mylan) Protease 200 unit, Amylase 3600 unit, Lipase 5000 unit Creon Micro Pancreatin 60.12mg gastro-resistant granules | 20 gram p £31.50 Powder ▶Pancrex (Essential Pharmaceuticals Ltd) Protease 1400 unit, Lipase 25000 unit, Amylase 30000 unit Pancrex V oral powder sugar-free | 300 gram p £224.00 Capsule ▶Pancrex (Essential Pharmaceuticals Ltd) Protease 430 unit, Lipase 8000 unit, Amylase 9000 unit Pancrex V capsules | 300 capsule p £53.20 Stoma care Stoma care Description of condition A stoma is an artificial opening on the abdomen to divert flow of faeces or urine into an external pouch located outside of the body. This procedure may be temporary or permanent. Colostomy and ileostomy are the most common forms of stoma but a gastrostomy, jejunostomy, duodenostomy or caecostomy may also be performed. Understanding the type and extent of surgical intervention in each patient is crucial in managing the patient’s pharmaceutical needs correctly. Overview Prescribing for patients with stoma calls for special care due to modifications in drug delivery, resulting in a higher risk of sub-optimal absorption. The following is a brief account of some of the main points to be borne in mind. Enteric-coated and modified-release medicines are unsuitable, particularly in patients with an ileostomy, as there may not be sufficient release of active ingredient. Soluble tablets, liquids, capsules or uncoated tablets are more suitable due to their quicker dissolution. When a solid- dose form such as a capsule or a tablet is given, the contents of the ostomy bag should be checked for any remnants. Preparations containing sorbitol as an excipient should be avoided, due to its laxative side effects. Analgesics Opioid analgesics may cause troublesome constipation in colostomy patients. When a non-opioid analgesic is required, paracetamol is usually suitable. Anti-inflammatory analgesics may cause gastric irritation and bleeding; faecal output should be monitored for traces of blood. Antacids The tendency to diarrhoea from magnesium salts or constipation from aluminium or calcium salts may be increased in patients with stoma. Antisecretory drugs The gastric acid secretion often increases stoma output. Proton pump inhibitors and somatostatin analogues (octreotide p. 1002 and lanreotide p. 1001) are often used to reduce this risk. Antidiarrhoeal drugs Loperamide hydrochloride p. 71 and codeine phosphate p. 475 reduce intestinal motility and decrease water and sodium output from an ileostomy. Loperamide hydrochloride circulates through the enterohepatic circulation, which is disrupted in patients with a short bowel; high doses of loperamide hydrochloride may be required. Codeine phosphate can be added if response with loperamide hydrochloride alone is inadequate. Digoxin Patients with a stoma are particularly susceptible to hypokalaemia if taking digoxin p. 116, due to fluid and sodium depletion. Potassium supplements or a potassium- sparing diuretic may be advisable with monitoring for early signs of toxicity. Diuretics Diuretics should be used with caution in patients with an ileostomy or with urostomy as they may become excessively dehydrated and potassium depletion may easily occur. It is usually advisable to use a potassium-sparing diuretic. Iron preparations Iron preparations may cause loose stools and sore skin in Gastro-intestinal system these patients. If this is troublesome and if iron is definitely indicated, an intramuscular iron preparation should be used. Modified-release preparations should be avoided for the reasons given above. Laxatives Laxatives should not be used in patients with an ileostomy where possible as they may cause rapid and severe loss of water and electrolytes. Colostomy patients may suffer from constipation and whenever possible should be treated by increasing fluid intake or dietary fibre. Bulk-forming drugs can be tried. If they are insufficient, as small a dose as possible of a stimulant laxative such as senna p. 67 can be used with caution. Potassium supplements Liquid formulations are preferred to modified-release formulations. The daily dose should be split to avoid osmotic diarrhoea. Care of stoma Patients and their carers are usually given advice about the use of cleansing agents, protective creams, lotions, deodorants, or sealants whilst in hospital, either by the surgeon or by stoma care nurses. Voluntary organisations offer help and support to patients with stoma. Chapter 2 Cardiovascular system Cardiovascular system CONTENTS Arrhythmias page 106 Bleeding disorders Coagulation factor deficiencies 2.1 Subarachnoid haemorrhage 2.2 Blood clots Blocked catheters and lines 3.1 Thromboembolism 3.2 Blood pressure conditions Hypertension 4.1 4.1a Hypertension associated with phaeochromocytoma 4.1b Hypertensive crises Arrhythmias Arrhythmias Overview Management of an arrhythmia requires precise diagnosis of the type of arrhythmia, and electrocardiography is essential; underlying causes such as heart failure require appropriate treatment. For recommendations on the management of acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre- existing cardiovascular disease, see NICE rapid guidelines: Acute myocardial injury (available at: www.nice.org.uk/ guidance/ng171). For further information on COVID-19, see COVID-19 p. 656. Ectopic beats If ectopic beats are spontaneous and the patient has a normal heart, treatment is rarely required and reassurance to the patient will often suffice. If they are particularly troublesome, beta-blockers are sometimes effective and may be safer than other suppressant drugs. Atrial fibrillation Treatment of patients with atrial fibrillation aims to reduce symptoms and prevent complications, especially stroke. All patients with atrial fibrillation should be assessed for their risk of stroke and thromboembolism. Atrial fibrillation can be managed by either controlling the ventricular rate (‘rate control’) or by attempting to restore and maintain sinus rhythm (‘rhythm control’). At any stage if treatment fails to control symptoms, or, if symptoms reoccur after cardioversion and specialised management is required, referral should be made within 4 weeks. If drug treatment fails to control the symptoms of atrial fibrillation or is unsuitable, ablation strategies can be considered. Review anticoagulation, stroke, and bleeding risk at least annually in all patients with atrial fibrillation. Acute presentation All patients with life-threatening haemodynamic instability caused by new-onset atrial fibrillation should undergo emergency electrical cardioversion without delaying to 4.1c Pulmonary hypertension page 194 Hypotension and shock 4.2 Cardiovascular risk assessment and prevention Heart failure Hyperlipidaemia Myocardial ischaemia Acute coronary syndromes 8.1 8.1a Cardiac arrest Oedema Vascular disease Vein malformations 10.1 achieve anticoagulation. In patients presenting acutely but without life-threatening haemodynamic instability, rate or rhythm control can be offered if the onset of arrhythmia is less than 48 hours; rate control is preferred if onset is more than 48 hours or uncertain. Consideration of pharmacological or electrical cardioversion should be based on clinical circumstances. If pharmacological cardioversion has been agreed, intravenous amiodarone hydrochloride p. 112, or alternatively flecainide acetate p. 110, can be used (amiodarone hydrochloride is preferred if there is structural heart disease). If urgent rate control is required, a beta- blocker or verapamil hydrochloride p. 175 can be given intravenously. Cardioversion Sinus rhythm can be restored by electrical cardioversion, or pharmacological cardioversion with an oral or intravenous antiarrhythmic drug e.g. flecainide acetate or amiodarone hydrochloride. If atrial fibrillation has been present for more than 48 hours, electrical cardioversion is preferred and should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced, and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks; prior to cardioversion, offer rate control as appropriate. Drug treatment Rate control is the preferred first-line drug treatment strategy for atrial fibrillation except in patients with new-onset atrial fibrillation, atrial flutter suitable for an ablation strategy, atrial fibrillation with a reversible cause, or if rhythm control is more suitable based on clinical judgement. Ventricular rate can be controlled with a standard beta-blocker (not sotalol hydrochloride p. 115) or a rate-limiting calcium channel blocker such as diltiazem hydrochloride p. 169 [unlicensed indication], or verapamil hydrochloride as monotherapy. Choice of drug should be based on individual symptoms, heart rate, comorbidities, and patient preference. Digoxin p. 116 is usually only effective for controlling the ventricular rate at rest, and should therefore only be used as monotherapy in predominantly sedentary patients with non- paroxysmal atrial fibrillation. When a single drug fails to adequately control the ventricular rate, a combination of two drugs including a beta-blocker, digoxin, or diltiazem hydrochloride can be used. If symptoms are not controlled with a combination of two drugs, a rhythm-control strategy should be considered. If ventricular function is diminished, the combination of a beta-blocker (that is licensed for use in heart failure) and digoxin is preferred. Digoxin is also used when atrial fibrillation is accompanied by congestive heart failure. If drug treatment is required to maintain sinus rhythm (‘rhythm control’) post-cardioversion, a standard beta- blocker is used. If a standard beta-blocker is not appropriate or is ineffective, consider an oral anti-arrhythmic drug such as sotalol hydrochloride, flecainide acetate, propafenone hydrochloride p. 111, or amiodarone hydrochloride; dronedarone p. 113 may be considered in paroxysmal or persistent atrial fibrillation (see NICE guidance). If necessary, amiodarone hydrochloride can be started 4 weeks before and continuing for up to 12 months after electrical cardioversion to increase success of the procedure, and to maintain sinus rhythm. Flecainide acetate or propafenone hydrochloride should not be given when there is known ischaemic or structural heart disease. Consider amiodarone hydrochloride in patients with left ventricular impairment or heart failure. Paroxysmal atrial fibrillation In symptomatic paroxysmal atrial fibrillation, ventricular rhythm is controlled with a standard beta-blocker. Alternatively, if symptoms persist or a standard beta-blocker is not appropriate, an oral anti-arrhythmic drug such as dronedarone (see NICE guidance), sotalol hydrochloride, flecainide acetate, propafenone hydrochloride, or amiodarone hydrochloride can be given (see also Paroxysmal supraventricular tachycardia and Supraventricular arrhythmias). In selected patients with infrequent episodes of symptomatic paroxysmal atrial fibrillation, sinus rhythm can be restored using the ‘pill-in-the-pocket’ approach; this involves the patient taking oral flecainide acetate or propafenone hydrochloride to self-treat an episode of atrial fibrillation when it occurs. Stroke prevention All patients with atrial fibrillation should be assessed for their risk of stroke and the need for thromboprophylaxis; this needs to be balanced with the patient’s risk of bleeding; a NICE guideline (NICE clinical guideline 180 (June 2014). Atrial fibrillation: The management of atrial fibrillation) recommends using the CHA2 DS2-VASc assessment tool for stroke risk and the HAS-BLED tool for bleeding risk prior to and during anticoagulation. Risk factors for stroke taken into account by CHA2 DS2-VASc include prior ischaemic stroke, transient ischaemic attacks, or thromboembolic events, heart failure, left ventricular systolic dysfunction, vascular disease, diabetes, hypertension, females, and patients over 65 years. Patients with a very low risk of stroke (CHA2 DS2- VASc score of 0 for men or 1 for women) do not require an antithrombotic for stroke prevention. Parenteral anticoagulation should be offered to patients with new- onset atrial fibrillation who are receiving subtherapeutic or no anticoagulation therapy until assessment is made, and appropriate anticoagulation is started. Oral anticoagulation should be offered to patients with confirmed diagnosis of atrial fibrillation in whom sinus rhythm has not been successfully restored within 48 hours of onset, patients who have had, or are at high risk of recurrence of atrial fibrillation such as those with structural heart disease, prolonged history of atrial fibrillation (more than 12 months), a history of failed attempts at cardioversion, and patients whom the risk of stroke outweighs the risk of bleeding. Anticoagulation treatment should not be withheld solely because of the risk of falls, and choice of treatment should be based on clinical features and patient preferences. Oral anticoagulation may be with a vitamin K antagonist (e.g warfarin sodium p. 150), or in non-valvular atrial fibrillation with apixaban p. 133, dabigatran etexilate p. 146, edoxaban p. 135, or rivaroxaban p. 137. Anticoagulants are also indicated during cardioversion procedures. Aspirin p. 130 is less effective than warfarin sodium at preventing emboli; the modest benefit is offset by the risk of bleeding, and aspirin should not be offered as monotherapy solely for stroke prevention in atrial Cardiovascular system fibrillation. If anticoagulant treatment is contra-indicated or not tolerated, left atrial appendage occlusion can be considered. Atrial flutter Like atrial fibrillation, treatment options for atrial flutter involve either controlling the ventricular rate or attempting to restore and maintain sinus rhythm. However, atrial flutter generally responds less well to drug treatment than atrial fibrillation. Control of the ventricular rate is usually an interim measure pending restoration of sinus rhythm. Ventricular rate can be controlled by administration of a beta-blocker, diltiazem hydrochloride p. 169 [unlicensed indication], or verapamil hydrochloride p. 175; an intravenous beta-blocker or verapamil hydrochloride is preferred for rapid control. Digoxin p. 116 can be added if rate control remains inadequate, and may be particularly useful in those with heart failure. Conversion to sinus rhythm can be achieved by electrical cardioversion (by cardiac pacing or direct current), pharmacological cardioversion, or catheter ablation. If the duration of atrial flutter is unknown, or it has lasted for over 48 hours, cardioversion should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks. Direct current cardioversion is usually the treatment of choice when rapid conversion to sinus rhythm is necessary (e.g. when atrial flutter is associated with haemodynamic compromise); catheter ablation is preferred for the treatment of recurrent atrial flutter. There is a limited role for anti-arrhythmic drugs as their use is not always successful. Flecainide acetate p. 110 or propafenone hydrochloride p. 111 can slow atrial flutter, resulting in 1:1 conduction to the ventricles, and should therefore be prescribed in conjunction with a ventricular rate controlling drug such as a beta-blocker, diltiazem hydrochloride [unlicensed indication], or verapamil hydrochloride. Amiodarone hydrochloride p. 112 can be used when other drug treatments are contra-indicated or ineffective. All patients should be assessed for their risk of stroke and the need for thromboprophylaxis; the choice of anticoagulant is based on the same criteria as for atrial fibrillation. Paroxysmal supraventricular tachycardia This will often terminate spontaneously or with reflex vagal stimulation such as a Valsalva manoeuvre, immersing the face in ice-cold water, or carotid sinus massage; such manoeuvres should be performed with ECG monitoring. If the effects of reflex vagal stimulation are transient or ineffective, or if the arrhythmia is causing severe symptoms, intravenous adenosine p. 114 should be given. If adenosine is ineffective or contra-indicated, intravenous verapamil hydrochloride is an alternative, but it should be avoided in patients recently treated with beta-blockers. Failure to terminate paroxysmal supraventricular tachycardia with reflex vagal stimulation or drug treatment may suggest an arrhythmia of atrial origin, such as focal atrial tachycardia or atrial flutter. Treatment with direct current cardioversion is needed in haemodynamically unstable patients or when the above measures have failed to restore sinus rhythm (and an alternative diagnosis has not been found). Recurrent episodes of paroxysmal supraventricular tachycardia can be treated by catheter ablation, or prevented with drugs such as diltiazem hydrochloride, verapamil hydrochloride, beta-blockers including sotalol hydrochloride Cardiovascular system p. 115, flecainide acetate or propafenone hydrochloride. Arrhythmias after myocardial infarction In patients with a paroxysmal tachycardia or rapid irregularity of the pulse it is best not to administer an anti- arrhythmic until an ECG record has been obtained. Bradycardia, particularly if complicated by hypotension, should be treated with an intravenous dose of atropine sulfate p. 1404 the dose may be repeated if necessary. If there is a risk of asystole, or if the patient is unstable and has failed to respond to atropine sulfate, adrenaline/epinephrine p. 236 should be given by intravenous infusion, and the dose adjusted according to response. For further advice, refer to the most recent recommendations of the Resuscitation Council (UK) available at www.resus.org.uk. Ventricular tachycardia Pulseless ventricular tachycardia or ventricular fibrillation should be treated with immediate defibrillation (see Cardiopulmonary resuscitation). Patients with unstable sustained ventricular tachycardia, who continue to deteriorate with signs of hypotension or reduced cardiac output, should receive direct current cardioversion to restore sinus rhythm. If this fails, intravenous amiodarone hydrochloride should be administered and direct current cardioversion repeated. Patients with sustained ventricular tachycardia who are haemodynamically stable can be treated with intravenous anti-arrhythmic drugs. Amiodarone hydrochloride is the preferred drug. Flecainide acetate, propafenone hydrochloride, and, although less effective, lidocaine hydrochloride p. 109 have all been used. If sinus rhythm is not restored, direct current cardioversion or pacing should be considered. Catheter ablation is an alternative if cessation of the arrhythmia is not urgent. Non-sustained ventricular tachycardia can be treated with a beta-blocker. All patients presenting with ventricular tachycardia should be referred to a specialist. Following restoration of sinus rhythm, patients who remain at high risk of cardiac arrest will require maintenance therapy. Most patients will be treated with an implantable cardioverter defibrillator. Beta- blockers or sotalol hydrochloride (in place of a standard beta-blocker), or amiodarone hydrochloride (in combination with a standard beta-blocker), can be used in addition to the device in some patients; alternatively, they can be used alone when use of an implantable cardioverter defibrillator is not appropriate. Torsade de pointes Torsade de pointes is a form of ventricular tachycardia associated with a long QT syndrome (usually drug-induced, but other factors including hypokalaemia, severe bradycardia, and genetic predisposition are also implicated). Episodes are usually self-limiting, but are frequently recurrent and can cause impairment or loss of consciousness. If not controlled, the arrhythmia can progress to ventricular fibrillation and sometimes death. Intravenous infusion of magnesium sulfate p. 1112 is usually effective. A beta-blocker (but not sotalol hydrochloride) and atrial (or ventricular) pacing can be considered. Anti- arrhythmics can further prolong the QT interval, thus worsening the condition. Anti-arrhythmic drugs Anti-arrhythmic drugs can be classified clinically into those that act on supraventricular arrhythmias (e.g. verapamil hydrochloride), those that act on both supraventricular and ventricular arrhythmias (e.g. amiodarone hydrochloride), and those that act on ventricular arrhythmias (e.g. lidocaine hydrochloride). Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity (the Vaughan Williams classification) although this classification is of less clinical significance: . Class I: membrane stabilising drugs (e.g. lidocaine, flecainide) . Class II: beta-blockers . Class III: amiodarone; sotalol (also Class II) . Class IV: calcium-channel blockers (includes verapamil but not dihydropyridines) The negative inotropic effects of anti-arrhythmic drugs tend to be additive. Therefore special care should be taken if two or more are used, especially if myocardial function is impaired. Most drugs that are effective in countering arrhythmias can also provoke them in some circumstances; moreover, hypokalaemia enhances the arrhythmogenic (pro- arrhythmic) effect of many drugs. Supraventricular arrhythmias Adenosine p. 114 is usually the treatment of choice for terminating paroxysmal supraventricular tachycardia. As it has a very short duration of action (half-life only about 8 to 10 seconds, but prolonged in those taking dipyridamole p. 132), most side-effects are short lived. Unlike verapamil hydrochloride p. 175, adenosine can be used after a beta- blocker. Verapamil hydrochloride may be preferable to adenosine in asthma. Oral administration of a cardiac glycoside (such as digoxin p. 116) slows the ventricular response in cases of atrial fibrillation and atrial flutter. However, intravenous infusion of digoxin is rarely effective for rapid control of ventricular rate. Cardiac glycosides are contra-indicated in supraventricular arrhythmias associated with accessory conducting pathways (e.g. Wolff- Parkinson-White syndrome). Verapamil hydrochloride is usually effective for supraventricular tachycardias. An initial intravenous dose (important: serious beta-blocker interaction hazard) may be followed by oral treatment; hypotension may occur with large doses. It should not be used for tachyarrhythmias where the QRS complex is wide (i.e. broad complex) unless a supraventricular origin has been established beyond reasonable doubt. It is also contra-indicated in atrial fibrillation or atrial flutter associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome). It should not be used in children with arrhythmias without specialist advice; some supraventricular arrhythmias in childhood can be accelerated by verapamil hydrochloride with dangerous consequences. Intravenous administration of a beta-blocker such as esmolol hydrochloride p. 166 or propranolol hydrochloride p. 162, can achieve rapid control of the ventricular rate. Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride p. 112, beta- blockers, disopyramide p. 110, flecainide acetate p. 110, procainamide (available from ‘special-order’ manufacturers or specialist importing companies), and propafenone hydrochloride p. 111. Supraventricular and ventricular arrhythmias Amiodarone hydrochloride is used in the treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated. It can be used for paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, and ventricular fibrillation. It can also be used for tachyarrhythmias associated with Wolff- Parkinson- White syndrome. It should be initiated only under hospital or specialist supervision. Amiodarone hydrochloride may be given by intravenous infusion as well as by mouth, and has the advantage of causing little or no myocardial depression. Unlike oral amiodarone hydrochloride, intravenous amiodarone hydrochloride acts relatively rapidly. Intravenous injection of amiodarone hydrochloride can be used in cardiopulmonary resuscitation for ventricular fibrillation or pulseless tachycardia unresponsive to other interventions. Amiodarone hydrochloride has a very long half-life (extending to several weeks) and only needs to be given once daily (but high doses can cause nausea unless divided). Many weeks or months may be required to achieve steady-state plasma-amiodarone concentration; this is particularly important when drug interactions are likely. Beta-blockers act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. Sotalol hydrochloride p. 115 has a role in the management of ventricular arrhythmias. Disopyramide can be given by intravenous injection to control arrhythmias after myocardial infarction (including those not responding to lidocaine hydrochloride p. 109), but it impairs cardiac contractility. Oral administration of disopyramide is useful, but it has an antimuscarinic effect which limits its use in patients susceptible to angle-closure glaucoma or with prostatic hyperplasia. Flecainide acetate belongs to the same general class as lidocaine hydrochloride and may be of value for serious symptomatic ventricular arrhythmias. It may also be indicated for junctional re-entry tachycardias and for paroxysmal atrial fibrillation. However, it can precipitate serious arrhythmias in a small minority of patients (including those with otherwise normal hearts). Propafenone hydrochloride is used for the prophylaxis and treatment of ventricular arrhythmias and also for some supraventricular arrhythmias. It has complex mechanisms of action, including weak beta-blocking activity (therefore caution is needed in obstructive airways disease—contra- indicated if severe). Drugs for supraventricular arrhythmias include adenosine, cardiac glycosides, and verapamil hydrochloride. Drugs for ventricular arrhythmias include lidocaine hydrochloride. Mexiletine and procainamide are both available from ‘special-order’ manufacturers or specialist importing companies. Mexiletine can be used for life-threatening ventricular arrhythmias; procainamide is given by intravenous injection to control ventricular arrhythmias. Ventricular arrhythmias Intravenous lidocaine hydrochloride can be used for the treatment of ventricular tachycardia in haemodynamically stable patients, and ventricular fibrillation and pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation, however it is no longer the anti-arrhythmic drug of first choice. Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride, beta- blockers, disopyramide, flecainide acetate, procainamide (available from ‘special- order’ manufacturers or specialist importing companies), and propafenone hydrochloride. Mexiletine is available from ‘special-order’ manufacturers or specialist importing companies for treatment of life- threatening ventricular arrhythmias. Advanced Pharmacy Services Patients with an arrhythmia may be eligible for the New Medicines Service / Medicine Use Review service provided by a community pharmacist. For further information, see Advanced Pharmacy Services in Medicines optimisation p. 18. Useful resources Patient decision aid: Atrial fibrillation: medicines to help reduce your risk of a stroke—what are the options? National Institute for Health and Care Excellence. June 2014. www.nice.org.uk/about/what-we-do/our-programmes/nice- guidance/nice-guidelines/shared-decision-making Other drugs used for Arrhythmias Acebutolol, p. 163. Metoprolol tartrate, p. 166. Nadolol, p. 161 Cardiovascular system ANTIARRHYTHMICS › CLASS IB
PDF pages 126, 127, 128, 129, 130, 131
Patients or carers should be given advice on administration. It is important to ensure adequate hydration at all times in patients receiving higher-strength pancreatin preparations. Medicines for Children leaflet: Pancreatin for pancreatic insufficiency www.medicinesforchildren.org.uk/pancreatin- pancreatic-insufficiency
PDF page 126
Initially 1–2 capsules, dose to be taken with
First-line fragment. Read the complete Indications and Dose section above.
PDF page 125
Initially 1–2 capsules, dose to be taken with
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
Initially 1–2 capsules, dose to be taken with
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
Initially 100 mg, for administration advice, see
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
Initially 1–2 capsules, dose to be taken with
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
Initially 1–2 capsules, dose to be taken during
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
2–6 capsules, dose to be taken with each meal
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126
0.5–2 g, to be taken before or with meals,
First-line fragment. Read the complete Indications and Dose section above.
PDF page 126